STO · ONCO.ST
Oncopeptides AB (publ)
SEK 1.67-SEK 0.04 (-2.22%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.75% below the high.
Loading market information…
OTC · NEVPF · USD
Stock price, earnings
Quote as of Mar 18, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Abliva AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 25.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Abliva AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Abliva AB (publ) is a pharmaceutical firm focused on developing novel treatments for primary mitochondrial disorders. Its product pipeline features KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions. Another compound, NV354, is undergoing preparations for clinical studies, specifically targeting primary mitochondrial diseases linked to Complex I deficiency. Beyond mitochondrial diseases, the company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for traumatic brain injury. Abliva collaborates with a range of institutions and companies, including Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. Founded in 2000 and based in Lund, Sweden, the company adopted its current name, Abliva AB (publ), in May 2020, having previously operated as NeuroVive Pharmaceutical AB (publ).
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:03 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.67-SEK 0.04 (-2.22%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.75% below the high.
$0.54-$0.00 (-0.37%)
Mindset Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.74% below the high.
$0.82$0.00 (0.0%)
Medivir AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 8.89% below the high.
$4.08$0.00 (0.0%)
Relief Therapeutics Holding AG’s quoted price sits in the lower half of its reported 52-week range, 73.06% below the high.
$1.96+$0.00 (0.0%)
MedPeer,Inc.’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
$0.11-$0.01 (-9.69%)
Small Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.36% below the high.
$5.73$0.00 (0.0%)
Alpha Cognition Inc.: Healthcare · Biotechnology.
€1.16-€0.04 (-3.67%)
Herantis Pharma Oyj’s quoted price sits in the lower half of its reported 52-week range, 59.72% below the high.
